Boditech Med Inc. (206640.KQ)
KRW 17340.0
(0.29%)
KRW 17340.0
(0.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -31.92 Billion KRW | -83.84% |
| 2022 | -17.36 Billion KRW | 45.65% |
| 2021 | -31.95 Billion KRW | -163.62% |
| 2020 | -12.12 Billion KRW | -54.67% |
| 2019 | -7.83 Billion KRW | -2115.02% |
| 2018 | 388.89 Million KRW | -95.29% |
| 2017 | 8.26 Billion KRW | 179.02% |
| 2016 | -10.45 Billion KRW | -24.06% |
| 2015 | -8.42 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -24.48 Billion KRW | 23.32% |
| 2024 Q2 | -23.92 Billion KRW | 2.26% |
| 2023 Q2 | -35.68 Billion KRW | -38.14% |
| 2023 Q4 | -31.92 Billion KRW | -18.77% |
| 2023 FY | -31.92 Billion KRW | -83.84% |
| 2023 Q3 | -26.88 Billion KRW | 24.66% |
| 2023 Q1 | -25.82 Billion KRW | -48.73% |
| 2022 Q1 | -27.86 Billion KRW | 12.79% |
| 2022 Q3 | -19.3 Billion KRW | -52.6% |
| 2022 Q2 | -12.65 Billion KRW | 54.59% |
| 2022 Q4 | -17.36 Billion KRW | 10.05% |
| 2022 FY | -17.36 Billion KRW | 45.65% |
| 2021 FY | -31.95 Billion KRW | -163.62% |
| 2021 Q1 | -12.29 Billion KRW | 4.3% |
| 2021 Q2 | -25.93 Billion KRW | -110.99% |
| 2021 Q3 | -35.34 Billion KRW | -36.3% |
| 2021 Q4 | -31.95 Billion KRW | 9.61% |
| 2020 Q2 | -9.83 Billion KRW | 26.82% |
| 2020 Q4 | -12.84 Billion KRW | 54.08% |
| 2020 Q3 | -27.97 Billion KRW | -184.47% |
| 2020 Q1 | -13.43 Billion KRW | -57.66% |
| 2020 FY | -12.12 Billion KRW | -54.67% |
| 2019 Q2 | 4.29 Billion KRW | -11.89% |
| 2019 FY | -7.83 Billion KRW | -2115.02% |
| 2019 Q4 | -8.52 Billion KRW | -136.21% |
| 2019 Q3 | -3.6 Billion KRW | -183.91% |
| 2019 Q1 | 4.87 Billion KRW | 1154.63% |
| 2018 Q2 | 8 Billion KRW | 95.91% |
| 2018 FY | 388.89 Million KRW | -95.29% |
| 2018 Q4 | 388.89 Million KRW | -92.07% |
| 2018 Q1 | 4.08 Billion KRW | -27.49% |
| 2018 Q3 | 4.9 Billion KRW | -38.76% |
| 2017 FY | 8.26 Billion KRW | 179.02% |
| 2017 Q1 | -10.72 Billion KRW | -3.76% |
| 2017 Q2 | -8.44 Billion KRW | 21.28% |
| 2017 Q3 | -5.83 Billion KRW | 30.82% |
| 2017 Q4 | 5.63 Billion KRW | 196.51% |
| 2016 Q3 | -1.5 Billion KRW | -220.62% |
| 2016 Q1 | -398.54 Million KRW | 96.79% |
| 2016 Q2 | 1.24 Billion KRW | 413.4% |
| 2016 FY | -10.45 Billion KRW | -24.06% |
| 2016 Q4 | -10.33 Billion KRW | -585.99% |
| 2015 Q3 | -3.4 Billion KRW | 0.0% |
| 2015 FY | -8.42 Billion KRW | 0.0% |
| 2015 Q4 | -12.4 Billion KRW | -263.84% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 18.96 Billion KRW | 268.377% |
| CMG Pharmaceutical Co., Ltd. | 18.78 Billion KRW | 269.964% |
| Celltrion Pharm, Inc. | 142.81 Billion KRW | 122.355% |
| Huons Global Co., Ltd. | 13.26 Billion KRW | 340.682% |
| DongKook Pharmaceutical Co., Ltd. | 44.19 Billion KRW | 172.241% |
| Enzychem Lifesciences Corporation | -9.81 Billion KRW | -225.339% |
| Humedix Co., Ltd. | -77.54 Billion KRW | 58.829% |
| EuBiologics Co., Ltd. | 4.88 Billion KRW | 754.027% |
| FutureChem Co.,Ltd | -4.93 Billion KRW | -547.51% |
| Huons Co., Ltd. | 73.9 Billion KRW | 143.196% |
| BNC Korea Co., Ltd. | -67.65 Billion KRW | 52.807% |
| AptaBio Therapeutics Inc. | -12.08 Billion KRW | -164.241% |